Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience
- PMID: 17006418
Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience
Abstract
Aim: With this 8-month study, we wanted to evaluate the efficacy of continuous intrathecal baclofen infusion delivery by a programmable pump for severe spasticity according to patient selection criteria, implantation technique and related parameters, and outcome after the initial follow-up period.
Methods: Intrathecal baclofen infusion was initiated in 30 patients within 24 h after a test dose of the agent resulted positive in spinal anaesthesia. During the procedure and the follow-up period, the following parameters were measured: incidence of anaesthesiological or surgical complications and adverse events, postdural puncture headache, prolonged motor block, difficulty in wound healing, infection, necessity to remove the pump; clinical response as measured on the Ashworth and spasms scales, quality of sleep, autonomy, quality of life and pain before and after intrathecal baclofen therapy.
Results: Perioperative vital parameters (mean duration of the operation, 86+/-13 min) were stable; no motor block or postdural puncture headache, early or late infection developed. The 1 case of delayed wound healing resolved with treatment; a dislocated catheter was repositioned in 1 other case. The differences in changes between pre- and posttreatment were statistically significant, with best results obtained on rigidity and pain. The mean length of hospital stay was 8+/-2 days. Baclofen tolerance was observed in 1 case, but resolved after baclofen holiday with morphine. One case of pump malfunctioning was resolved with replacement of the device; no new neurological deficits occurred thereafter.
Conclusions: The good clinical response to treatment of spasticity and rigidity, improved quality of life, pain reduction and patient satisfaction with short length of admission demonstrate the efficacy of intrathecal baclofen therapy. Safe and efficacious, this mode of treatment appears to be the gold standard for treating severe spasticity.
Similar articles
-
A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.Arch Phys Med Rehabil. 2005 Nov;86(11):2165-71. doi: 10.1016/j.apmr.2005.05.018. Arch Phys Med Rehabil. 2005. PMID: 16271565 Clinical Trial.
-
Continuous intrathecal infusion of baclofen in patients with spasticity caused by spinal cord injuries.Neurosurg Rev. 2002 Aug;25(4):228-30. doi: 10.1007/s10143-002-0221-1. Epub 2002 Apr 13. Neurosurg Rev. 2002. PMID: 12172730
-
[The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects].Przegl Lek. 2007;64 Suppl 2:18-21. Przegl Lek. 2007. PMID: 17953274 Polish.
-
[Management of increase in spasticity in patients with intrathecal baclofen pumps].Ann Readapt Med Phys. 2007 Mar;50(2):93-9. doi: 10.1016/j.annrmp.2006.09.005. Epub 2006 Nov 10. Ann Readapt Med Phys. 2007. PMID: 17098318 Review. French.
-
Intrathecal baclofen withdrawal: a case report and review of the literature.Childs Nerv Syst. 2002 Oct;18(9-10):522-5. doi: 10.1007/s00381-002-0634-8. Epub 2002 Jul 23. Childs Nerv Syst. 2002. PMID: 12382179 Review.
Cited by
-
Understanding the reasons for delayed referral for intrathecal baclofen therapy in pediatric patients with severe spasticity.Childs Nerv Syst. 2015 Mar;31(3):405-13. doi: 10.1007/s00381-014-2591-4. Epub 2014 Nov 16. Childs Nerv Syst. 2015. PMID: 25398671
MeSH terms
Substances
LinkOut - more resources
Full Text Sources